FASTING:YES

ESTRONE

Analyte	Value	
ESTRONE	**34**	Reference Range: < OR = 68 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE (DIALYSIS) AND TOTAL,MS

Analyte	Value	
TESTOSTERONE, TOTAL, MS	**494**	Reference Range: 250-1100 ng/dL

For additional information, please refer to http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMSFAQ165 (This link is being provided for informational/ educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE	**113.6**	Reference Range: 35.0-155.0 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

FSH AND LH

Analyte	Value	
FSH	**3.5**	Reference Range: 1.6-8.0 mIU/mL
LH	**2.4**	Reference Range: 1.5-9.3 mIU/mL

ALBUMIN

Analyte	Value	
ALBUMIN	**4.4**	Reference Range: 3.6-5.1 g/dL

TSH

Analyte	Value	
TSH	**0.72**	Reference Range: 0.40-4.50 mIU/L

T4, FREE

Analyte	Value	
T4, FREE	**1.3**	Reference Range: 0.8-1.8 ng/dL

T3, TOTAL

Analyte	Value	
T3, TOTAL	119	Reference Range: 76-181 ng/dL

CBC (H/H, RBC, INDICES, WBC, PLT)

Analyte	Value	
WHITE BLOOD CELL COUNT	4.7	Reference Range: 3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT	5.33	Reference Range: 4.20-5.80 Million/uL
HEMOGLOBIN	15.9	Reference Range: 13.2-17.1 g/dL
HEMATOCRIT	46.2	Reference Range: 38.5-50.0 %
MCV	86.7	Reference Range: 80.0-100.0 fL
MCH	29.8	Reference Range: 27.0-33.0 pg
MCHC	34.4	Reference Range: 32.0-36.0 g/dL
RDW	13.2	Reference Range: 11.0-15.0 %
PLATELET COUNT	268	Reference Range: 140-400 Thousand/uL
MPV	9.9	Reference Range: 7.5-12.5 fL

SEX HORMONE BINDING GLOBULIN

Analyte	Value	
SEX HORMONE BINDING GLOBULIN	16	Reference Range: 10-50 nmol/L

DHEA SULFATE

Analyte	Value	
DHEA SULFATE	157	Reference Range: 106-464 mcg/dL

PROLACTIN

Analyte	Value	
PROLACTIN	11.1	Reference Range: 2.0-18.0 ng/mL

ESTRADIOL

Analyte	Value	
ESTRADIOL	27	Reference Range: < OR = 39 pg/mL

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

PSA (FREE AND TOTAL)

Analyte	Value

PSA, TOTAL	**0.7**	Reference Range: < OR = 4.0 ng/mL
PSA, FREE	**0.2**	ng/mL
PSA, % FREE	**29**	Reference Range: >25 % (calc)

```
PSA(ng/mL)      Free PSA(%)     Estimated(x) Probability
                                     of Cancer(as%)
0-2.5              (*)              Approx. 1
2.6-4.0(1)         0-27(2)                  24(3)
4.1-10(4)          0-10                     56
                    11-15                    28
                    16-20                    20
                    21-25                    16
                    >or =26                  8
>10(+)              N/A                     >50

References:(1)Catalona et al.:Urology 60: 469-474 (2002)
           (2)Catalona et al.:J.Urol 168: 922-925 (2002)
              Free PSA(%)   Sensitivity(%)  Specificity(%)
              < or = 25          85              19
              < or = 30          93               9
           (3)Catalona et al.:JAMA 277: 1452-1455 (1997)
           (4)Catalona et al.:JAMA 279: 1542-1547 (1998)

(x)These estimates vary with age, ethnicity, family
   history and DRE results.
(*)The diagnostic usefulness of % Free PSA has not been
   established in patients with total PSA below 2.6 ng/mL
(+)In men with PSA above 10 ng/mL, prostate cancer risk is
   determined by total PSA alone.

The Total PSA value from this assay system is
standardized against the equimolar PSA standard.
The test result will be approximately 20% higher
when compared to the WHO-standardized Total PSA
(Siemens assay). Comparison of serial PSA results
should be interpreted with this fact in mind.

PSA was performed using the Beckman Coulter
Immunoassay method. Values obtained from different
assay methods cannot be used interchangeably. PSA
levels, regardless of value, should not be interpreted
as absolute evidence of the presence or absence of
disease.
```

Key

Priority Out of Range Out of Range